The stock is trading above its 50 DMA of $22.21, and the 200 DMA of $20.83. The fact that the 50 DMA is above the 200 DMA indicates the strength of the stock. Barring the recent correction after hitting the high of $26, it has been on an uptrend since January when it made its low of $17.20. The stock is likely to be active as the earnings are going to be declared on May 9, 2013. The strong rebound from the recent low of $22.53 indicates that investors have faith in the stock. The volumes have improved but are not very robust. The company declared good results last time around, and there are expectations for it to repeat its performance. The margins in the business are low, but the increased awareness amongst consumers about benefits of organic foods / dietary supplements is increasing the size of the market. Consequently, more and more players are entering the segment and competition is increasing. ChromaDex Corporation (CDXC) recently launched a new low caffeine drink containing its proprietary ingredient pterostilbene which is expected to receive good response in view of the harmful effects of high caffeine products. CDXC's pterostilbene is a successful discovery, which has already led to a successful product BluScience that the company sold in a very good deal. For the full year, NGVC has given a guidance of 28% growth, and the number of stores is also likely to increase. Comparing with the offer price of $15, the stock has already rewarded investors with great returns. Price to sales remains reasonable at 1.52, but the valuations are getting a little stretched with a forward P/E of 40. This is mainly because the business in which it operates is low margin. The price to book is 7.22 which is high. One can invest / trade with a stop loss at $22.